BR112021023923A2 - Agonistas de receptor de peptídeo 1 similares a glucagon - Google Patents

Agonistas de receptor de peptídeo 1 similares a glucagon

Info

Publication number
BR112021023923A2
BR112021023923A2 BR112021023923A BR112021023923A BR112021023923A2 BR 112021023923 A2 BR112021023923 A2 BR 112021023923A2 BR 112021023923 A BR112021023923 A BR 112021023923A BR 112021023923 A BR112021023923 A BR 112021023923A BR 112021023923 A2 BR112021023923 A2 BR 112021023923A2
Authority
BR
Brazil
Prior art keywords
glucagon
peptide
receptor agonists
compound
formula
Prior art date
Application number
BR112021023923A
Other languages
English (en)
Inventor
Andrew Coates David
Fucheng Qu
Daniel HO Joseph
Todd Fields
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112021023923A2 publication Critical patent/BR112021023923A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

agonistas de receptor de peptídeo 1 similares a glucagon. em uma modalidade, a presente invenção refere-se a um composto da fórmula: ou um sal farmaceuticamente aceitável do mesmo, e métodos de utilização deste composto para o tratamento de diabetes mellitus tipo ii.
BR112021023923A 2019-06-28 2020-06-19 Agonistas de receptor de peptídeo 1 similares a glucagon BR112021023923A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962868117P 2019-06-28 2019-06-28
US201962904906P 2019-09-24 2019-09-24
PCT/US2020/038617 WO2020263695A1 (en) 2019-06-28 2020-06-19 Glucagon-like peptide 1 receptor agonists

Publications (1)

Publication Number Publication Date
BR112021023923A2 true BR112021023923A2 (pt) 2022-01-25

Family

ID=71575804

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021023923A BR112021023923A2 (pt) 2019-06-28 2020-06-19 Agonistas de receptor de peptídeo 1 similares a glucagon

Country Status (30)

Country Link
US (2) US11655242B2 (pt)
EP (2) EP3989972B1 (pt)
JP (1) JP7256300B2 (pt)
KR (1) KR20220012924A (pt)
CN (1) CN114008033A (pt)
AU (1) AU2020309064B2 (pt)
BR (1) BR112021023923A2 (pt)
CA (1) CA3144055C (pt)
CL (1) CL2021003419A1 (pt)
CO (1) CO2021017433A2 (pt)
CR (1) CR20210599A (pt)
DK (1) DK3989972T3 (pt)
DO (1) DOP2021000273A (pt)
EC (1) ECSP21093576A (pt)
ES (1) ES2970173T3 (pt)
FI (1) FI3989972T3 (pt)
HR (1) HRP20231586T1 (pt)
HU (1) HUE065080T2 (pt)
IL (1) IL288479A (pt)
JO (1) JOP20210337A1 (pt)
LT (1) LT3989972T (pt)
MD (1) MD3989972T2 (pt)
MX (1) MX2021015328A (pt)
PE (1) PE20220590A1 (pt)
PL (1) PL3989972T3 (pt)
PT (1) PT3989972T (pt)
RS (1) RS64940B1 (pt)
SI (1) SI3989972T1 (pt)
TW (1) TWI751585B (pt)
WO (1) WO2020263695A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10954221B2 (en) 2019-04-12 2021-03-23 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
CR20220178A (es) 2019-10-25 2022-06-15 Gilead Sciences Inc Compuestos moduladores de glp-1r
US20230051318A1 (en) * 2019-12-02 2023-02-16 Hyundai Pharm Co., Ltd. Glp-1 receptor agonist
JP2023513272A (ja) 2020-02-07 2023-03-30 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
JP2023515404A (ja) * 2020-02-13 2023-04-13 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
IL296336A (en) * 2020-03-18 2022-11-01 Lg Chemical Ltd A agonist for the glp-1 receptor, a pharmaceutical preparation containing it and a method for its preparation
EP4119555A4 (en) * 2020-03-18 2023-08-23 Lg Chem, Ltd. GLP-1 RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION THEREOF AND PROCESS FOR MANUFACTURE THEREOF
MX2023001311A (es) 2020-08-06 2023-04-18 Gasherbrum Bio Inc Agonistas heterociclicos de glp-1.
CN116406360A (zh) 2020-08-28 2023-07-07 加舒布鲁姆生物公司 杂环glp-1激动剂
US11851419B2 (en) 2020-11-20 2023-12-26 Gilead Sciences, Inc. GLP-1R modulating compounds
CA3200245A1 (en) * 2020-11-27 2022-06-02 Junjun Wu Benzimidazole derivative and preparation method therefor and medical use thereof
WO2022184849A1 (en) 2021-03-04 2022-09-09 Les Laboratoires Servier Glp-1r agonists, uses and pharmaceutical compositions thereof
WO2022202864A1 (ja) 2021-03-24 2022-09-29 塩野義製薬株式会社 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
JP2024514259A (ja) * 2021-04-08 2024-03-29 エルジー・ケム・リミテッド Ｇｌｐ－１受容体作動薬、それを含む薬学的組成物、およびその製造方法
KR20230173708A (ko) 2021-04-21 2023-12-27 길리애드 사이언시즈, 인코포레이티드 카르복시-벤즈이미다졸 glp-1r 조절 화합물
WO2022235717A1 (en) * 2021-05-03 2022-11-10 Carmot Therapeutics, Inc. Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
WO2022246019A1 (en) 2021-05-20 2022-11-24 Eli Lilly And Company Macrocyclic glucagon-like peptide 1 receptor agonists
CN118215478A (zh) 2021-09-08 2024-06-18 盐野义制药株式会社 用于预防和治疗与抗肥胖作用有关的疾病的药物
WO2023057414A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
WO2023057429A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
CA3233131A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators
WO2023111145A1 (en) 2021-12-16 2023-06-22 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
WO2023111144A1 (en) 2021-12-16 2023-06-22 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
WO2023169436A1 (zh) * 2022-03-08 2023-09-14 广州市联瑞制药有限公司 苯并双环类化合物及其制备方法和应用
WO2024041609A1 (zh) * 2022-08-24 2024-02-29 广州市联瑞制药有限公司 苯并双环类化合物及其制备方法和应用
WO2024102625A1 (en) 2022-11-11 2024-05-16 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists
WO2024107781A1 (en) 2022-11-16 2024-05-23 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120053180A1 (en) * 2010-08-27 2012-03-01 Chemizon, A Division Of Optomagic Co., Ltd. Cyclohexane analogues as gpr119 agonists
AR087451A1 (es) * 2011-08-17 2014-03-26 Lilly Co Eli Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
WO2018098781A1 (en) * 2016-12-01 2018-06-07 Eli Lilly And Company Pyrrolidinone compounds
PE20191501A1 (es) * 2016-12-16 2019-10-22 Pfizer Agonistas receptores de glp-1 y sus usos de los mismos
TWI707683B (zh) 2018-06-13 2020-10-21 美商輝瑞股份有限公司 Ｇｌｐ－１受體促效劑及其用途
PT3806855T (pt) 2018-06-15 2023-05-03 Pfizer Agonistas dos receptores de glp-1 e suas utilizações
CU20210042A7 (es) 2018-11-22 2022-01-13 Qilu Regor Therapeutics Inc Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen
MA55627A (fr) 2019-04-12 2022-02-16 Qilu Regor Therapeutics Inc Agonistes de glp-1r et leurs utilisations
US10954221B2 (en) * 2019-04-12 2021-03-23 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
WO2021018023A1 (zh) 2019-08-01 2021-02-04 济南泰达领创医药技术有限公司 小分子glp-1受体调节剂
CR20220178A (es) 2019-10-25 2022-06-15 Gilead Sciences Inc Compuestos moduladores de glp-1r
US11643403B2 (en) 2019-11-15 2023-05-09 Ildong Pharmaceutical Co., Ltd. GLP-1 receptor agonist and use thereof
US20230051318A1 (en) 2019-12-02 2023-02-16 Hyundai Pharm Co., Ltd. Glp-1 receptor agonist
US20220288030A1 (en) 2020-01-29 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
JP2023515404A (ja) 2020-02-13 2023-04-13 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
IL296336A (en) 2020-03-18 2022-11-01 Lg Chemical Ltd A agonist for the glp-1 receptor, a pharmaceutical preparation containing it and a method for its preparation
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
JP2023524493A (ja) 2020-04-29 2023-06-12 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト

Also Published As

Publication number Publication date
DK3989972T3 (da) 2023-12-04
PL3989972T3 (pl) 2024-03-25
PE20220590A1 (es) 2022-04-22
FI3989972T3 (fi) 2024-01-24
AU2020309064A1 (en) 2022-01-27
CN114008033A (zh) 2022-02-01
CO2021017433A2 (es) 2022-04-19
CL2021003419A1 (es) 2022-09-23
SI3989972T1 (sl) 2024-01-31
KR20220012924A (ko) 2022-02-04
US20200407347A1 (en) 2020-12-31
DOP2021000273A (es) 2022-03-15
ECSP21093576A (es) 2022-01-31
ES2970173T3 (es) 2024-05-27
MX2021015328A (es) 2022-01-18
WO2020263695A1 (en) 2020-12-30
HRP20231586T1 (hr) 2024-03-15
JP2022540044A (ja) 2022-09-14
CA3144055C (en) 2024-01-02
EP4302826A3 (en) 2024-04-17
EP3989972B1 (en) 2023-11-08
TWI751585B (zh) 2022-01-01
RS64940B1 (sr) 2024-01-31
US20230250092A1 (en) 2023-08-10
EP4302826A2 (en) 2024-01-10
TW202115040A (zh) 2021-04-16
CR20210599A (es) 2021-12-22
EP3989972A1 (en) 2022-05-04
JP7256300B2 (ja) 2023-04-11
HUE065080T2 (hu) 2024-04-28
PT3989972T (pt) 2023-12-04
MD3989972T2 (ro) 2024-05-31
LT3989972T (lt) 2023-12-27
JOP20210337A1 (ar) 2023-01-30
CA3144055A1 (en) 2020-12-30
AU2020309064B2 (en) 2023-08-17
IL288479A (en) 2022-01-01
US11655242B2 (en) 2023-05-23

Similar Documents

Publication Publication Date Title
BR112021023923A2 (pt) Agonistas de receptor de peptídeo 1 similares a glucagon
CL2017001760A1 (es) Compuestos co-agonistas de gip y glp-1
CL2017003185A1 (es) Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)
BR112017008160A8 (pt) Peptídeo, composição, métodos para tratamento de um paciente ou indivíduo e para tratamento de uma doença metabólica, e, usos de um peptídeo e de uma composição
CO2019006917A2 (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip
PE20220938A1 (es) Compuestos agonistas de gipr
UA114710C2 (uk) Похідне оксинтомодуліну та фармацевтична композиція для запобігання або лікування ожиріння, яка його містить
EA201590525A1 (ru) Слитые белки для лечения метаболического синдрома
PE20200606A1 (es) Composiciones solidas para administracion oral
EA201991316A1 (ru) Конъюгаты, содержащие двойной агонист glp-1/глюкагона, линкер и гиалуроновую кислоту
BR112013029062A2 (pt) lixisenatida e metformina para o tratamento de diabetes tipo 2
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
BR112017025000A2 (pt) tratamento de hipoglicemia pós-bariátrica com exendina (9-39)
PE20211595A1 (es) Compuestos de 2,6-diaminopiridina
CO2021016870A2 (es) Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa
BR112017018388A2 (pt) tratamento de pacientes com diabetes mellitus tipo 2
PE20210116A1 (es) Administracion oral de analogos del peptido glp-1
CL2017001843A1 (es) Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2.
BR112018071991A2 (pt) forma de cristal da dapaglifozina e método para a preparação e uso da mesma
BR112023022851A2 (pt) Agonistas de receptor de peptídeo 1 similares ao glucagon macrocíclico
BR112015017909A2 (pt) redução do risco de doença autoimune
BR112022018979A2 (pt) Medicamento para tratamento de dor
BR112022004401A2 (pt) Tratamento de diabetes mellitus tipo 2
AR109895A1 (es) Compuestos cíclicos de péptido tirosina tirosina como moduladores de neuropéptido y receptores
BR112021026790A2 (pt) Composto de pirimidina-5-carboxamida